Loading...

Allan Flach, MD, PharmD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentOphthalmology
Address10 Koret Way
San Francisco CA 94117
Phone415-476-0678
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoResidency
    University of California, San FranciscoM.D.1971 Medicine
    University of California, San FranciscoPharm.D.1967 Pharmacy

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Laties AM, Flach AJ, Baldycheva I, Rak I, Earley W, Pathak S. Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial. J Psychopharmacol. 2015 Jan; 29(1):69-79. PMID: 25315830.
      View in: PubMed
    2. Flach AJ. Amsler grids for chloroquine toxicity. Ophthalmology. 2011 Oct; 118(10):2099; author reply 2099-100. PMID: 21968178.
      View in: PubMed
    3. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010 Mar-Apr; 55(2):108-33. PMID: 20159228.
      View in: PubMed
    4. Flach AJ. Intraoperative floppy iris syndrome: pathophysiology, prevention, and treatment. Trans Am Ophthalmol Soc. 2009 Dec; 107:234-9. PMID: 20126500; PMCID: PMC2814568.
    5. Flach AJ. Proposed mandate for instructions and labeling regarding the use of eye drops. Arch Ophthalmol. 2009 Sep; 127(9):1207-9. PMID: 19752433.
      View in: PubMed
    6. Flach AJ. Debunking myths in physician-industry conflicts of interest. Am J Ophthalmol. 2009 Mar; 147(3):562-3; author reply 563-4. PMID: 19217965.
      View in: PubMed
    7. Flach AJ. The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studies. Trans Am Ophthalmol Soc. 2008; 106:138-45; discussion 145-8. PMID: 19277229; PMCID: PMC2646444.
    8. Flach AJ. Improving the risk-benefit relationship and informed consent for patients treated with hydroxychloroquine. Trans Am Ophthalmol Soc. 2007; 105:191-4; discussion 195-7. PMID: 18427609; PMCID: PMC2258132.
    9. Flach AJ. Misuse and abuse of topically applied nonsteroidal anti-inflammatory drugs. Cornea. 2006 Dec; 25(10):1265-6. PMID: 17172917.
      View in: PubMed
    10. Shapiro BL, Petrovic V, Lee SE, Flach A, McCaffery S, O'Brien JM. Choroidal detachment following the use of tamsulosin (Flomax). Am J Ophthalmol. 2007 Feb; 143(2):351-3. PMID: 17258532.
      View in: PubMed
    11. Waterbury LD, Flach AJ. Comparison of ketorolac tromethamine, diclofenac sodium, and loteprednol etabonate in an animal model of ocular inflammation. J Ocul Pharmacol Ther. 2006 Jun; 22(3):155-9. PMID: 16808675.
      View in: PubMed
    12. Waterbury LD, Flach AJ. Efficacy of low concentrations of ketorolac tromethamine in animal models of ocular inflammation. J Ocul Pharmacol Ther. 2004 Aug; 20(4):345-52. PMID: 15321029.
      View in: PubMed
    13. Flach AJ. Does medical treatment influence the success of trabeculectomy? Trans Am Ophthalmol Soc. 2004; 102:219-23; discussion 223-4. PMID: 15747760; PMCID: PMC1280102.
    14. Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin. 2002; 42(1):1-11. PMID: 12189605.
      View in: PubMed
    15. Flach AJ. Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. Trans Am Ophthalmol Soc. 2002; 100:215-22; discussion 222-4. PMID: 12545695; PMCID: PMC1358964.